Dual PPARα/γ agonist saroglitazar improves liver histopathology and biochemistry in experimental NASH models

• المؤلفون الرئيسيون: Jain, Mukul R., Giri, Suresh R., Bhoi, Bibhuti, Trivedi, Chitrang, Rath, Akshyaya, Rathod, Rohan, Ranvir, Ramchandra, Kadam, Shekhar, Patel, Hiren, Swain, Prabodha, Roy, Sib Sankar, Das, Nabanita, Karmakar, Eshani, Wahli, Walter, Patel, Pankaj R.
• مؤلفون آخرون: Lee Kong Chian School of Medicine (LKCMedicine)
• التنسيق: مقال
• اللغة: English
• منشور في: 2019
• الموضوعات: NAFLD; Science::Medicine; Dual‐PPAR Agonist
• الوصول للمادة أونلاين: https://hdl.handle.net/10356/106322; http://hdl.handle.net/10220/49606
• المؤسسة: Nanyang Technological University

Background & Aims: Non‐alcoholic fatty liver disease (NAFLD) and non‐alcoholic steatohepatitis (NASH) are common clinico‐pathological conditions that affect millions of patients worldwide. In this study, the efficacy of saroglitazar, a novel PPARα/γ agonist, was assessed in models of NAFLD/NASH....